Yan Chuan, Yang Qiqi, Zhang Songfa, Millar David G, Alpert Eric J, Do Daniel, Veloso Alexandra, Brunson Dalton C, Drapkin Benjamin J, Stanzione Marcello, Scarfò Irene, Moore John C, Iyer Sowmya, Qin Qian, Wei Yun, McCarthy Karin M, Rawls John F, Dyson Nick J, Cobbold Mark, Maus Marcela V, Langenau David M
Molecular Pathology Unit, Massachusetts General Research Institute, Charlestown, MA.
Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA.
J Exp Med. 2021 Oct 4;218(10). doi: 10.1084/jem.20210314. Epub 2021 Aug 20.
T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization of T cell immune responses at single-cell resolution in vivo. Here, optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with chimeric antigen receptor T (CAR T) cells, bispecific T cell engagers (BiTEs), and antibody peptide epitope conjugates (APECs), allowing real-time single-cell visualization of T cell-based immunotherapies in vivo. This work uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses. We also established EGFR-targeted immunotherapies as a powerful approach to kill rhabdomyosarcoma muscle cancers, providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease.
T细胞免疫疗法彻底改变了一部分癌症的治疗方式。然而,一个主要障碍是缺乏简便且可预测的临床前动物模型,这种模型能够在体内以单细胞分辨率动态可视化T细胞免疫反应。在这里,将光学透明的免疫缺陷斑马鱼与荧光标记的人类癌症细胞以及嵌合抗原受体T(CAR T)细胞、双特异性T细胞衔接器(BiTEs)和抗体肽表位缀合物(APECs)一起移植,从而能够在体内对基于T细胞的免疫疗法进行实时单细胞可视化。这项工作揭示了这些免疫疗法在T细胞浸润、肿瘤细胞结合和杀伤动力学方面的重要差异,并建立了早期终点分析来预测治疗反应。我们还确立了表皮生长因子受体(EGFR)靶向免疫疗法是一种治疗横纹肌肉瘤肌肉癌的有效方法,为评估针对这种疾病的更广泛的T细胞免疫疗法提供了有力的临床前理论依据。